Observational clinical evaluation of the safety and efficacy of the Solitaire FR Device in acute ischemic stroke patients requiring mechanical thrombectomy when used according to its Instructions For Use. Study sponsor is ev3. Study is ongoing but not recruiting patients.

Prospective, observational, cohort study to determine the revascularization rate, clinical efficacy, and safety of the CE-marked MindFrame System in ischemic stroke patients. Study sponsor is MindFrame, Inc. The study is ongoing, but not recruiting participants.

Randomized trial to determine the safety and efficacy of intra-arterial reperfusion in acute ischemic stroke patients ineligible for IV-TPA as selected by physiologic imaging. Study sponsor is Medical University of South Carolina. This study is not yet open for participant recruitment.

Randomized, controlled trial to assess the safety and effectiveness of the Penumbra System as an adjunctive treatment to IV-TPA in patients with acute ischemic stroke from large vessel occlusion in the brain. Patients must be eligible to receive IV-TPA and have evidence of a large clot burden (clot length > 8 mm). Study sponsor is Penumbra, Inc. This study is currently recruiting participants.

Observational cohort study whose primary aim is to gather data on the “real world” experience of the Penumbra System and to determine if there is a correlation between the imaging-defined size of the ischemic penumbra at admission and the outcomes in patients already treated by the System. Study sponsor is Penumbra, Inc. This study is ongoing, but not recruiting participants.

Randomized, controlled trial to determine if patients with acute ischemic stroke due to a large vessel occlusion treated with combined IV-TPA and Solitaire FR within 6 hours of symptom onset have less stroke-related disability than those patients treated with IV TPA alone. Study sponsor is Covidien. This study is currently recruiting participants.

Retrospective, observational, multicenter study comparing a direct aspiration, first pass technique to traditional thrombectomy devices in patients undergoing thrombectomy for acute stroke. Study sponsor is Medical University of South Carolina. This study is not yet open for participant recruitment.

Prospective, randomized, controlled, multicenter trial evaluating the safety and effectiveness of the Penumbra Separator 3D as a component of the Penumbra System for the revascularization of large vessel occlusion in acute ischemic stroke. Patients will be assigned to either the Penumbra System with the Separator 3D or the Penumbra System alone without the Separator 3D. Study sponsor is Penumbra, Inc. This study is currently recruiting participants.

Randomized pilot trial comparing endovascular reperfusion therapy to IV-TPA in patients able to receive the assigned treatment within 4.5 hours of symptom onset. Study sponsor is Mayo Clinic. This study is currently recruiting participants.

Randomized, controlled trial comparing intra-arterial reperfusion therapy with the Solitaire device after standard dose IV-TPA to IV-TPA alone in patients with acute ischemic stroke. Patients must be eligible to receive IV-TPA within 4.5 hours of symptom onset, and demonstrate a large vessel occlusion and mismatch on imaging. Study sponsor is National Stroke Research Institute, Australia. This study is currently recruiting participants.

Non-randomized study to evaluate the safety and feasibility of directed, intra-arterial magnesium measurement and therapy, through endovascular access, in acute stroke patients. Study sponsor is University of Southern California. This study is currently recruiting participants.

Observational cohort study of patients with acute ischemic stroke treated with IV or IA thrombolysis in a Swiss stroke unit. Clinical and radiographical data will be evaluated. Study sponsor is University Hospital Inselspital, Berne. This study is currently recruiting participants.

Randomized trial studying the safety and effectiveness of using CT Perfusion studies as an indicator to treat stroke patients with unknown time of onset. Patients will be assigned to standard medical therapy, IV thrombolysis, or intra-arterial intervention. Study sponsor is Jacobs Neurological Institute. This study is currently recruiting participants.

Randomized, sham-controlled, multicenter trial designed to determine the safety and efficacy of ALD-401 delivered by intracarotid infusion in treating patients with primary ischemic stroke. ALD-401 is made from the stroke patient's bone marrow and infused 13-19 days after the stroke. Study sponsor is Aldagen. This study is currently recruiting participants.

Prospective, randomized study to evaluate whether general anesthesia or sedation technique is preferable during embolectomy for acute stroke, measured in terms of three month neurological impairment and complication frequency between the methods. Study sponsor is Sahlgrenska University Hospital, Sweden. This study is currently recruiting participants.

Open label, nonrandomized, multicenter safety study of Plasmin (Human) in patients with stroke due to a clot in the middle cerebral artery. Plasmin will be administered through a catheter into the thrombus within 9 hours of stroke onset. Three doses of Plasmin will be tested in 3 different groups of patients. Study sponsor is Grifols Therapeutics Inc. This study is currently recruiting participants.

Nonrandomized safety and tolerability study of an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute total or partial anterior circulation syndrome. Study sponsor is Imperial College London. This study is currently recruiting participants.

Observational cohort study to gather information on predictors of good or poor clinical outcome following mechanical recanalization therapies for acute ischemic stroke. Study sponsor is Goethe University. This study is currently recruiting participants.

In the first part of this study, the investigators propose to develop a fully automated CTP analysis program. Part two is a prospective cohort study to demonstrate that this CTP analysis program can help accurately identify acute stroke patients who are likely to benefit from endovascular therapy. Study sponsor is Stanford University. This study is currently recruiting participants.

Non-randomized, single group study to determine the safety and effectiveness of the Penumbra System in a stroke cohort who presents within 8 hours from symptom onset and with a known core infarct volume on admission. The study will also determine if there is a correlation between infarct volume and functional outcome in treated patients at 90 days post-procedure. Study sponsor is Penumbra, Inc. This study is ongoing, but not recruiting participants.